New pamphlet on the NIF mouse as a liver fibrosis model
Read our new pamphlet on the NIF mouse as a model for studies of liver fibrosis. The NIF mouse can be used both as a model for tests of drugs to treat general liver fibrosis, [...]
InfiCure Bio received a seal of excellence from EU
The application to Horizon 2020 SME Instrument Phase II submitted by InfiCure Bio i January 2019 was awarded a seal of excellence. This means that the application passed the score set by EU for grant [...]
InfiCure Bio will present at Keystone Symposium in January 2019
Julia Nilsson, Research Associate at InfiCure Bio, will be presenting at the Keystone Symposium: "Integrated Pathways of Disease in NASH and NAFLD" in Santa Fee January 20-24 2019. Julia will present new data on the [...]
Anti-Fibrotic Drug Development Summit
The CEO of InfiCure Bio was one of 28 Expert Speakers at the Anti-Fibrotic Drug Development Summit held in Boston November 27-29 2018. InfiCure Bio was presenting new data on the unique NIF mouse as [...]
NASH summit in Frankfurt
InfiCure Bio is present at the 2nd NASH summit in Europe held in Frankfurt. We are presenting our new models for NASH, the NIF-HFD mouse and the MEL-HFD mouse. InfiCure did also moderate the round [...]
InfiCure Bio is nominated in the category “Spin-off company of the year”
InfiCure Bio is nominated in the category "Spin-off company of the year" at UmeåGalan 2018 and we are very happy and excited about it. UmeåGalan will be held on November 8th and this is an [...]